Newsroom
  • December 1 , 2023

    AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

    Read more
  • November 29 , 2023

    FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies

    Read more
  • November 24 , 2023

    China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

    Read more
  • November 23 , 2023

    Telitacicept (brand name: 泰愛®) formally granted full approval from conditional approval by NMPA for use in combination with conventional therapy in adult patients with active and auto-antibody positive systemic lupus erythematosus

    Read more
  • November 22 , 2023

    Merck seals $610M biobucks deal to acquire preclinical neurodegenerative biotech Caraway

    Read more
  • November 21 , 2023

    Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Read more
  • November 20 , 2023

    FDA signs off on new uses for Astellas and Pfizer's Xtandi, Merck's Keytruda

    Read more
  • November 18 , 2023

    AstraZeneca's first-in-class FDA approval for Truqap marred by surprise restriction

    Read more
  • November 17 , 2023

    BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

    Read more
  • November 14 , 2023

    Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

    Read more
  • November 9 , 2023

    HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

    Read more
  • October 30 , 2023

    Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

    Read more
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
If you would like to get in touch with us, please click here. Contact us